UNLIMITED TURBO LONG - TANDEM DIABETES CARE Stock

Certificat

DE000PC9XY37

Real-time Boerse Frankfurt Warrants 03:50:38 2024-07-11 am EDT
0.99 EUR -2.94% Intraday chart for UNLIMITED TURBO LONG - TANDEM DIABETES CARE
Current month+61.90%
1 month-28.17%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-11 0.99 -2.94%
24-07-10 1.02 +20.00%
24-07-09 0.85 +6.25%
24-07-08 0.8 +25.00%
24-07-05 0.64 0.00%

Real-time Boerse Frankfurt Warrants

Last update July 11, 2024 at 03:50 am EDT

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying TANDEM DIABETES CARE, INC.
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PC9XY3
ISINDE000PC9XY37
Date issued 2024-05-16
Strike 35.51 $
Maturity Unlimited
Parity 10 : 1
Emission price 0.93
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.86
Lowest since issue 0.48
Spread 0.07
Spread %6.60%

Company Profile

Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company, which manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of it AID systems, it offers pump integration with multiple CGM sensors.
Sector
-
More about the company

Ratings for Tandem Diabetes Care, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Tandem Diabetes Care, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
44.31 USD
Average target price
49.93 USD
Spread / Average Target
+12.69%
Consensus